A little history
myNEO was founded in 2018 by leading biotech entrepreneurs combining expertise from different academic institutions. Cedric Bogaert, Jan Van Den Berghe, and Wim van Criekinge have since then expanded the team with established domain in antigen discovery experts as well as ambitious talent to further grow the company's innovation and developments.
To date, myNEO has achieved several pivotal milestones in realizing its vision. These include:
- Development of state-of-the-art antigen prediction algorithms
- Discovery of novel, dark antigen targets called camyotopes
- (Co-)development of novel immunotherapeutics products via strategic collaborations or in-house, leading to 3 separate programs executing successful IND/CTA filings in 2025
- The publication of high-impact scientific papers
- ISO and regulatory approval for clinical use of technology
- Securing valuable intellectual property with multiple patents
- Receiving several prestigious awards (Most Disruptive Innovator, Forbes 30under30, Rising Star Fast50)
The people behind myNEO
Team
Cedric Bogaert
Chief Executive Officer & Co-founder
Bert Coessens PhD
Chief Operating Officer
Bruno Fant PhD
Chief Scientific Officer
Lien Lybaert PhD
Chief Development Officer
Lore Van Oudenhove
Chief Technology Officer
Lena Pfitzer
Senior data scientist
Gitta Boons PhD
Senior data scientist
Manon Montyne
Principal data scientist
Jens De Ceukeleire
Principal data scientist
Emiel Evenepoel
Junior bioinformatician
Marie Van Hecke PhD
Junior bioinformatician
Sofie Pontzeele
Executive assistant
John Castle PhD
Scientific advisor
John is Chief Data Scientist at Monte Rosa Therapeutics. John has deep expertise in biomarkers and therapy development using computational biology, AI, biotechnology and genomics. John pioneered bioinformatics and 'omics approaches to neoantigen identification for anti-tumor immunity, revolutionizing neoantigen vaccine and TCR platforms.
Prior to joining Monte Rosa Therapeutics, he was Associate Vice President for Translational Sciences at Agenus, served as associate director at Rosetta Inpharmatics/Merck & Co. and subsequently co-directed the Biomarker Development Center of Translational Oncology at the University of Mainz, Germany. John built the bioinformatics and genomics department at BioNTech AG.